论文部分内容阅读
目的探讨白蛋白结合型紫杉醇治疗晚期乳腺癌的疗效及安全性。方法 32例晚期乳腺癌患者,均使用单药白蛋白结合型紫杉醇行全身化疗,21 d为1个周期,根据WHO标准评价不良反应,每化疗2个周期后全面复查评价治疗效果。结果 32例患者共完成128周期化疗,平均4个周期,32例患者至少接受2周期全身化疗,所有患者均可评价疗效,其中完全缓解(CR)0例,部分缓解(PR)18例,稳定(SD)8例,进展(PD)6例,有效率为56.3%,临床收益率为81.3%,中位疾病进展时间(TTP)4.9个月。结论白蛋白结合型紫杉醇可用于多线治疗失败的晚期乳腺癌患者,有效率高,不良反应轻微,值得临床推广运用。
Objective To investigate the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced breast cancer. Methods Thirty - two patients with advanced breast cancer were treated with systemic chemotherapy with single albumin - bound paclitaxel and 21 days for one cycle. Adverse reactions were evaluated according to WHO criteria. The therapeutic effect was evaluated after 2 cycles of chemotherapy. Results 32 patients completed a total of 128 cycles of chemotherapy with an average of 4 cycles, 32 patients received at least 2 cycles of systemic chemotherapy, all patients can evaluate the efficacy of complete remission (CR) 0 cases, partial remission (PR) 18 cases, stable (SD) in 8 cases and progression (PD) in 6 cases. The effective rate was 56.3%, the clinical rate of return was 81.3% and the median time to progression of disease (TTP) was 4.9 months. Conclusions Albumin-bound paclitaxel can be used in patients with advanced breast cancer who have failed multi-line therapy, with high efficiency and mild adverse reactions. It is worthy of clinical application.